Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Mallinckrodt
Covington
UBS
Farmers Insurance
Harvard Business School
Baxter
Boehringer Ingelheim
US Department of Justice
Medtronic

Generated: October 19, 2017

DrugPatentWatch Database Preview

SIGNIFOR Drug Profile

« Back to Dashboard

What is the patent landscape for Signifor, and what generic Signifor alternatives are available?

Signifor is a drug marketed by Novartis and Novartis Pharms Corp and is included in two NDAs. There are four patents protecting this drug.

This drug has eighty-five patent family members in thirty-eight countries and sixteen supplementary protection certificates in eleven countries.

The generic ingredient in SIGNIFOR is pasireotide pamoate. One supplier is listed for this compound. Additional details are available on the pasireotide pamoate profile page.

Summary for Tradename: SIGNIFOR

US Patents:2
Applicants:2
NDAs:2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list5
Clinical Trials: see list5
Drug Prices:see details
DailyMed Link:SIGNIFOR at DailyMed

Pharmacology for Tradename: SIGNIFOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-003Dec 15, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-003Dec 15, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-001Dec 14, 2012RXYesNo► Subscribe► SubscribeYY ► Subscribe
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-001Dec 15, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-002Dec 15, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-002Dec 14, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-001Dec 14, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-003Dec 14, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-002Dec 15, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-002Dec 14, 2012RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: SIGNIFOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-002Dec 14, 2012► Subscribe► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-001Dec 14, 2012► Subscribe► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-003Dec 14, 2012► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SIGNIFOR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,939,625Somatostatin analogues► Subscribe
9,035,021Somatostatin analogues► Subscribe
8,822,637Somatostatin analogues► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SIGNIFOR

Country Document Number Estimated Expiration
Spain2305104► Subscribe
South Korea20030033008► Subscribe
European Patent Office1307486► Subscribe
Israel153920► Subscribe
Australia2001289778► Subscribe
Slovakia1212003► Subscribe
Russian Federation2355418► Subscribe
China1267451► Subscribe
Norway330706► Subscribe
Spain2328144► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SIGNIFOR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2012016,C1648934Lithuania► SubscribePRODUCT NAME: PASIREOTIDUM; REGISTRATION NO/DATE: EU/1/12/753/001 - EU/1/12/753/012, 0120424
12/027Ireland► SubscribePRODUCT NAME: PASIREOTIDE OR A SALT OR COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/12/753/001-EU/1/12/753/012 20120424
C0041France► SubscribePRODUCT NAME: CYCLO((4R)-4(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-) : PASIREOTIDE, OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/753/001 20120424
2012 00024Denmark► SubscribePRODUCT NAME: PASIREOTID OG FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER PASIREOTIDDIASPARTAT; REG. NO/DATE: EU/1/12/753/001-012 20120424
701Luxembourg► SubscribePRODUCT NAME: PASIREOTIDE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE OU UN HYDRATE QUI EN DERIVE . FIRST REGISTRATION: 20141121
00536Netherlands► SubscribePRODUCT NAME: PASIREOTIDE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN HET BIJZONDER PASIREOTIDEDI-ASPARTAAT; REGISTRATION NO/DATE: EU/1/12/753/001-012 20120424
0120019 00062Estonia► SubscribePRODUCT NAME: SIGNIFOR-PASIREOTIID;REG NO/DATE: C(2012) 2910 FINAL 24.04.2012
8Finland► Subscribe
C/GB12/030United Kingdom► SubscribePRODUCT NAME: CYCLO((4R)-4-(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-)), PASIREOTIDE, OR SALTS THEREOF; REGISTERED: UK EU/1/12/753/001-012 20120424
2012 00024Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
QuintilesIMS
Covington
Baxter
Boehringer Ingelheim
Colorcon
Queensland Health
Medtronic
Novartis
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot